Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis
| Autor: | Yiming Mu, Weijun Gu, Hongyan Liu, Guoqi Wang, Cheng-Zhi Wang, Xiao-Jian Ji |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Cinacalcet Nausea 030232 urology & nephrology lcsh:Medicine Calcimimetic Agents Placebo Article law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Renal Dialysis law Internal medicine medicine Humans 030212 general & internal medicine Renal Insufficiency Chronic lcsh:Science Adverse effect Randomized Controlled Trials as Topic Multidisciplinary business.industry Incidence (epidemiology) lcsh:R medicine.disease Vomiting Hyperparathyroidism Secondary lcsh:Q medicine.symptom business medicine.drug Kidney disease |
| Zdroj: | Scientific Reports, Vol 8, Iss 1, Pp 1-20 (2018) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | To assess the efficacy and safety of cinacalcet on secondary hyperparathyroidism in patients with chronic kidney disease, Pubmed, Embase, and the Cochrane Central Register of Controlled Trials were searched until March 2016. Trial sequential analysis (TSA) was conducted to control the risks of type I and II errors and calculate required information size (RIS). A total of 25 articles with 8481 participants were included. Compared with controls, cinacalcet administration did not reduce all-cause mortality (RR = 0.97, 95% CI = 0.89–1.05, P = 0.41, TSA-adjusted 95% CI = 0.86–1.08, RIS = 5260, n = 8386) or cardiovascular mortality (RR = 0.95, 95% CI = 0.83–1.07, P = 0.39, TSA-adjusted 95% CI = 0.70–1.26, RIS = 3780 n = 5418), but it reduced the incidence of parathyroidectomy (RR = 0.48, 95% CI = 0.40–0.50, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|